Achieve Life Sciences to Host Investor Meetings at 2026 J.P. Morgan Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Should l Buy ACHV?
Source: PRnewswire
- Meeting Schedule: Achieve Life Sciences will host in-person one-on-one investor meetings from January 12-15, 2026, at the J.P. Morgan Healthcare Conference in San Francisco, where CEO Rick Stewart will provide insights into the company's late-stage cytisinicline program, aiming to enhance investor confidence in future growth.
- NDA Progress: The New Drug Application for cytisinicline submitted in June 2025 has been accepted for review by the FDA, with a PDUFA date set for June 20, 2026, paving the way for commercialization in the tobacco dependence treatment market.
- Market Demand: With approximately 29 million adults in the U.S. smoking, and tobacco being the leading cause of preventable death, the development of cytisinicline not only addresses this significant market need but also has the potential to greatly improve public health outcomes.
- Clinical Research Results: Based on two successful Phase 3 studies and an open-label safety study, cytisinicline shows promise for smoking and vaping cessation, potentially becoming the first FDA-approved treatment specifically for e-cigarette cessation in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACHV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACHV
Wall Street analysts forecast ACHV stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.250
Low
12.00
Averages
15.50
High
19.00
Current: 4.250
Low
12.00
Averages
15.50
High
19.00
About ACHV
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Achieve Appoints New CEO and Secures $354 Million Funding
- New CEO Appointment: Achieve Life Sciences appointed Andrew D. Goldberg as CEO and Board member on Monday, who previously served as a Portfolio Manager at Marshall Wace, aiming to drive strategic transformation and enhance market competitiveness.
- Funding Agreement Secured: The company entered into a securities purchase agreement with leading healthcare investors, expected to raise up to approximately $354 million through a private placement, including about $180 million in initial funding, which will support clinical trials and working capital.
- Near-Term Milestones: Achieve anticipates launching cytisinicline for nicotine dependence in the first half of 2027; despite the FDA's potential rejection of its current application by June 20, the company plans to resubmit in Q4 2026, indicating confidence in future market prospects.
- Investor Sentiment Surge: On Stocktwits, retail sentiment around ACHV stock remains in the 'extremely bullish' territory, with message volume increasing from 'normal' to 'high', reflecting optimistic expectations among investors regarding potential acquisition opportunities post-drug approval.
See More
Achieve Life Sciences Secures $354 Million Financing for Drug Development
- Significant Financing: Achieve Life Sciences announced a securities purchase agreement that could raise up to $354 million in gross proceeds, including an upfront investment of approximately $180 million, providing substantial financial backing for the company's future initiatives.
- Clear Use of Funds: The proceeds will fund a Phase 3 trial for its smoking cessation drug candidate cytisinicline, support commercialization efforts in the e-cigarette market, and cover general corporate purposes, thereby enhancing the company's competitive position and product development capabilities.
- Milestone-Based Incentives: The financing agreement includes up to an additional $174 million tied to the exercise of milestone-based warrants, reflecting investor confidence in ACHV's future growth and the potential of its product offerings.
- Transaction Timeline: The private placement is expected to close on April 17, subject to customary conditions, providing a clear timeline for the infusion of capital that will accelerate clinical trials and market launch efforts.
See More
Achieve Life Sciences Publishes New Study on Cytisinicline
- Significant Research Findings: Achieve Life Sciences' study published in Nicotine & Tobacco Research reveals that cytisinicline demonstrates a 99% binding affinity at the α4β2 nicotinic receptor, indicating its effectiveness and potential in smoking cessation therapy.
- Tolerability Advantage: The study shows minimal binding (-8% displacement) to the 5-HT3 receptor, which helps explain the low incidence of adverse effects like nausea observed in clinical trials, potentially appealing to more smokers looking to quit.
- Urgent Market Demand: With approximately 25 million adults smoking and 18 million vaping in the U.S., and over half wanting to quit, there is a strong demand for new treatment options, making the development of cytisinicline timely and relevant.
- Regulatory Progress: Achieve Life Sciences has submitted a New Drug Application to the FDA, with a review date set for June 20, 2026, laying the groundwork for cytisinicline's market introduction and potentially transforming the landscape of smoking cessation therapies.
See More
Achieve Life Sciences Q4 2025 Earnings Call Insights
- Clinical Transition Progress: Achieve Life Sciences submitted the NDA for cytisinicline in June 2025, marking a shift from clinical to commercial focus, aiming to provide treatment for 25 million smokers and nearly 18 million vapers, demonstrating the company's keen awareness of market demand.
- Regulatory Milestone Achieved: The FDA accepted the NDA for cytisinicline and granted a National Priority Voucher for the vaping indication, providing an accelerated pathway to potential first-in-class approval for vaping cessation, which holds significant market potential.
- Financial Status Update: As of December 31, 2025, the company reported $36.4 million in cash and cash equivalents, with operating expenses of $14.7 million and a net loss of $14.7 million, reflecting ongoing investments in regulatory and commercial preparations despite a cash decrease from the previous quarter.
- Market Readiness and Risk Management: Management has engaged with payers approximately 40 times, emphasizing the differentiated profile of cytisinicline and the unmet market needs, while planning to initiate the ORCA-V2 Phase III trial in vaping cessation in the first half of 2026, showcasing the company's strategic focus on market access and supply chain security.
See More
Iran Allows 'Non-Hostile' Vessels to Transit Strait of Hormuz
- Transit Policy: Iran informed the International Maritime Organization that 'non-hostile' vessels may pass through the Strait of Hormuz if they coordinate with Iranian authorities, aiming to alleviate the shipping crisis caused by ongoing conflicts.
- Shipping Disruption Impact: Since the conflict erupted on February 28, shipping through the Strait has nearly ceased, leaving approximately 3,200 vessels stranded in the Gulf, affecting 20% of global oil shipments and trade for Gulf nations.
- Transit Costs: Some shipping operators have reportedly paid up to $2 million to secure safe passage, reflecting the significant impact of the current situation on shipping costs and operational risks.
- Humanitarian Corridor Exploration: The International Maritime Organization is considering establishing a humanitarian corridor to allow vessels facing fuel or supply shortages to safely exit the region, highlighting the importance of maritime safety amidst escalating tensions.
See More
Achieve Life Sciences Q4 Earnings Miss Expectations
- Earnings Performance: Achieve Life Sciences reported a Q4 GAAP EPS of -$0.28, missing expectations by $0.01, indicating challenges in profitability that could impact investor confidence moving forward.
- Cash Reserves Status: As of December 31, 2025, the company held $36.4 million in cash, cash equivalents, and marketable securities, which, while providing some liquidity, raises concerns about capital efficiency and future funding needs.
- Market Outlook Analysis: The company is viewed as a potential 'best tobacco stock' for 2026, bolstered by endorsement from Hunterbrook Capital, suggesting market anticipation for its upcoming product Cytisinicline, which may lead to stock price volatility.
- Ratings and Analysis: Seeking Alpha's Quant Rating assigns a Strong Buy to Achieve Life Sciences, reflecting analysts' optimism about the company's growth potential despite its current financial performance.
See More
Achieve Appoints New CEO and Secures $354 Million Funding
- New CEO Appointment: Achieve Life Sciences appointed Andrew D. Goldberg as CEO and Board member on Monday, who previously served as a Portfolio Manager at Marshall Wace, aiming to drive strategic transformation and enhance market competitiveness.
- Funding Agreement Secured: The company entered into a securities purchase agreement with leading healthcare investors, expected to raise up to approximately $354 million through a private placement, including about $180 million in initial funding, which will support clinical trials and working capital.
- Near-Term Milestones: Achieve anticipates launching cytisinicline for nicotine dependence in the first half of 2027; despite the FDA's potential rejection of its current application by June 20, the company plans to resubmit in Q4 2026, indicating confidence in future market prospects.
- Investor Sentiment Surge: On Stocktwits, retail sentiment around ACHV stock remains in the 'extremely bullish' territory, with message volume increasing from 'normal' to 'high', reflecting optimistic expectations among investors regarding potential acquisition opportunities post-drug approval.
See More
Achieve Life Sciences Secures $354 Million Financing for Drug Development
- Significant Financing: Achieve Life Sciences announced a securities purchase agreement that could raise up to $354 million in gross proceeds, including an upfront investment of approximately $180 million, providing substantial financial backing for the company's future initiatives.
- Clear Use of Funds: The proceeds will fund a Phase 3 trial for its smoking cessation drug candidate cytisinicline, support commercialization efforts in the e-cigarette market, and cover general corporate purposes, thereby enhancing the company's competitive position and product development capabilities.
- Milestone-Based Incentives: The financing agreement includes up to an additional $174 million tied to the exercise of milestone-based warrants, reflecting investor confidence in ACHV's future growth and the potential of its product offerings.
- Transaction Timeline: The private placement is expected to close on April 17, subject to customary conditions, providing a clear timeline for the infusion of capital that will accelerate clinical trials and market launch efforts.
See More
Achieve Life Sciences Publishes New Study on Cytisinicline
- Significant Research Findings: Achieve Life Sciences' study published in Nicotine & Tobacco Research reveals that cytisinicline demonstrates a 99% binding affinity at the α4β2 nicotinic receptor, indicating its effectiveness and potential in smoking cessation therapy.
- Tolerability Advantage: The study shows minimal binding (-8% displacement) to the 5-HT3 receptor, which helps explain the low incidence of adverse effects like nausea observed in clinical trials, potentially appealing to more smokers looking to quit.
- Urgent Market Demand: With approximately 25 million adults smoking and 18 million vaping in the U.S., and over half wanting to quit, there is a strong demand for new treatment options, making the development of cytisinicline timely and relevant.
- Regulatory Progress: Achieve Life Sciences has submitted a New Drug Application to the FDA, with a review date set for June 20, 2026, laying the groundwork for cytisinicline's market introduction and potentially transforming the landscape of smoking cessation therapies.
See More
Achieve Life Sciences Q4 2025 Earnings Call Insights
- Clinical Transition Progress: Achieve Life Sciences submitted the NDA for cytisinicline in June 2025, marking a shift from clinical to commercial focus, aiming to provide treatment for 25 million smokers and nearly 18 million vapers, demonstrating the company's keen awareness of market demand.
- Regulatory Milestone Achieved: The FDA accepted the NDA for cytisinicline and granted a National Priority Voucher for the vaping indication, providing an accelerated pathway to potential first-in-class approval for vaping cessation, which holds significant market potential.
- Financial Status Update: As of December 31, 2025, the company reported $36.4 million in cash and cash equivalents, with operating expenses of $14.7 million and a net loss of $14.7 million, reflecting ongoing investments in regulatory and commercial preparations despite a cash decrease from the previous quarter.
- Market Readiness and Risk Management: Management has engaged with payers approximately 40 times, emphasizing the differentiated profile of cytisinicline and the unmet market needs, while planning to initiate the ORCA-V2 Phase III trial in vaping cessation in the first half of 2026, showcasing the company's strategic focus on market access and supply chain security.
See More
Iran Allows 'Non-Hostile' Vessels to Transit Strait of Hormuz
- Transit Policy: Iran informed the International Maritime Organization that 'non-hostile' vessels may pass through the Strait of Hormuz if they coordinate with Iranian authorities, aiming to alleviate the shipping crisis caused by ongoing conflicts.
- Shipping Disruption Impact: Since the conflict erupted on February 28, shipping through the Strait has nearly ceased, leaving approximately 3,200 vessels stranded in the Gulf, affecting 20% of global oil shipments and trade for Gulf nations.
- Transit Costs: Some shipping operators have reportedly paid up to $2 million to secure safe passage, reflecting the significant impact of the current situation on shipping costs and operational risks.
- Humanitarian Corridor Exploration: The International Maritime Organization is considering establishing a humanitarian corridor to allow vessels facing fuel or supply shortages to safely exit the region, highlighting the importance of maritime safety amidst escalating tensions.
See More
Achieve Life Sciences Q4 Earnings Miss Expectations
- Earnings Performance: Achieve Life Sciences reported a Q4 GAAP EPS of -$0.28, missing expectations by $0.01, indicating challenges in profitability that could impact investor confidence moving forward.
- Cash Reserves Status: As of December 31, 2025, the company held $36.4 million in cash, cash equivalents, and marketable securities, which, while providing some liquidity, raises concerns about capital efficiency and future funding needs.
- Market Outlook Analysis: The company is viewed as a potential 'best tobacco stock' for 2026, bolstered by endorsement from Hunterbrook Capital, suggesting market anticipation for its upcoming product Cytisinicline, which may lead to stock price volatility.
- Ratings and Analysis: Seeking Alpha's Quant Rating assigns a Strong Buy to Achieve Life Sciences, reflecting analysts' optimism about the company's growth potential despite its current financial performance.
See More
